Previous Article | Next Article ![]()
Infection and Immunity, September 2007, p. 4440-4448, Vol. 75, No. 9
0019-9567/07/$08.00+0 doi:10.1128/IAI.02020-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Oral Biology, New Jersey Dental School, Newark, New Jersey 07103,1 New England Regional Primate Research Center, Harvard University, Southborough, Massachusetts 017722
Received 24 December 2006/ Returned for modification 4 February 2007/ Accepted 26 June 2007
|
|
|---|
was used to express apiA to further assess binding parameters. Results indicated that the apiA mutant strain showed significantly less binding to BECs than its parent strain (P
0.05). Further, binding mediated by ApiA was specific to BECs from humans and Old World primates, as seen in both wild-type A. actinomycetemcomitans and E. coli expressing ApiA (P
0.05). Pretreatment of wild-type A. actinomycetemcomitans cells with anti-ApiA antiserum reduced binding in a dose-dependent manner. The aae apiA double mutant completely abrogated A. actinomycetemcomitans binding to both human and Old World primate BECs. Taken together, these studies indicate that ApiA and Aae, in concert, modulate binding of A. actinomycetemcomitans to human BECs. Since the BEC is a prominent reservoir for A. actinomycetemcomitans, identification of this second adhesin could lead to important therapeutic strategies. |
|
|---|
In a recent publication our group demonstrated that Aae, an outer membrane protein, mediates attachment of A. actinomycetemcomitans (strain IDH781) to BECs from human and Old World primates, as opposed to BECs from other primates (7). Moreover, Escherichia coli expressing Aae demonstrated the same pattern of attachment, and thus binding was limited to BECs derived from humans and Old World primates. In a bacterial concentration-dependent BEC binding assay, results obtained from the aae mutant strain of A. actinomycetemcomitans and from E. coli expressing Aae indicated that the Aae adhesin had a high affinity for human BECs (7). It was also noted that aside from the Aae adhesin, a second, lower-affinity adhesin was present on the surface of A. actinomycetemcomitans that could also contribute to its binding to human BECs.
A. actinomycetemcomitans ApiA, also known as Omp100 (1), a member of the Yersinia adhesin (YadA) family of autotransporter adhesins, is a 100-kDa A. actinomycetemcomitans outer membrane protein adhesin that was shown to bind to epithelium (15). More recently, Li and colleagues demonstrated that ApiA expression resulted in binding to fibronectin and collagen as well as to epithelium (17). Although ApiA has been purported to be responsible for binding to different substrates, we decided to include apiA among a number of A. actinomycetemcomitans candidate adhesins to determine whether it could be the second BEC adhesin we observed.
The goals of this study were twofold: (i) to determine the gene responsible for this second A. actinomycetemcomitans adhesin, as noted in previous studies, and (ii) to determine the host range of this purported adhesin. If ApiA was identified as this second adhesin, an additional objective was to determine the effect of knocking out both apiA and aae on binding of A. actinomycetemcomitans to BECs derived from humans.
In this report we present evidence that ApiA exhibits a species-specific BEC binding phenotype similar to that of Aae and that a double knockout of apiA and aae completely abrogates the ability of A. actinomycetemcomitans to bind to human BECs.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Bacterial strains and plasmids
|
ori/KAN (Kmr) gene was inserted into the apiA open reading frame between bases 496 and 497 with the same promoter orientation as seen in the chromosome of IDH781N. Genetic complementation of apiA mutation. An ApiA expression plasmid was constructed by amplifying the apiA coding region from strain HK1651 (mapped to bp 602 to 1,489; GenBank accession no. AB064943) using a PCR primer pair (forward primer, CGCTGGATCCATAATGA AGA AAGTTTAGATGAC AT A TCAATTAT TTAAACACC; reverse primer, GACACTGCAGTTACCACTCAA AGTTTAAACC), which introduced a BamHI site 24 bp upstream from the apiA start codon and a PstI site immediately downstream from the apiA stop codon. The BamHI site and the PstI site are underlined in the forward primer and reverse primer, respectively. The PCR product was ligated into the BamHI/PstI sites of the broad-host-range plasmid pJAK16, which placed apiA under control of an isopropyl-ß-D-thiogalactopyranoside (IPTG)-inducible tac promoter (7). The resulting plasmid (named pJK654) was transformed into JK1051, and transformants were selected on agar containing 3 µg ml–1 of chloramphenicol.
Construction of apiA aae double-knockout strain. This strain was constructed by first amplifying the entire apiA coding region and flanking regions by PCR (mapped to bp 87 to 1,797; accession no. AB064943). The forward primer (AATTCGTTGTCATAATGG) is located 516 bp upstream from the apiA start codon, and the reverse primer (GAATTCCCGGGCTGTGCC) is located 307 bp downstream from its stop codon. The PCR amplicon was ligated into the plasmid vector pCR2.1 using a TOPO cloning kit (Invitrogen). Next, the 1,033-bp spectinomycin resistance (Smr) gene from plasmid pGMH491 (provided by David Figurski) was inserted between the two internal ClaI sites in apiA (bp 850 and 1,230; accession no. AB064943) so that the Smr gene was transcribed in the same orientation as apiA. The resulting mutagenic plasmid (linearized with ScaI) was used to transform strain JK1046 (aae::Kmr) to spectinomycin resistance (20 µg ml–1), which resulted in strain GJD1 (aae::Kmr apiA::Smr).
Construction of E. coli strain expressing functional ApiA.
DH5
chemically competent cells (Invitrogen) were used to express functional ApiA. The plasmid pJK654 was transformed into DH5
, following the manufacturer's instructions. Transformation of pJAK16 (the empty plasmid) was used as a control. For either the epithelial attachment assay or Western blotting, clones of DH5
/pJK654 (apiA+) and DH5a/pJAK16 vector alone or pJAK16 apiA mutant were picked from Luria-Bertani plates supplemented with 50 µg/ml chloramphenicol and inoculated into Luria-Bertani broth containing 50 µg/ml chloramphenicol. After overnight culture at 37°C with shaking at 250 rpm, an aliquot from each cell culture was reinoculated into fresh Luria-Bertani broth at 37°C with shaking at 250 rpm for 3 h. IPTG was added to cell cultures at a final concentration of 1 mM for 3 h prior to in vitro studies.
Isolation of mammalian oral epithelium. Human buccal and dorsal tongue epithelial cells were obtained from healthy adult volunteers. Collection of BECs from human volunteers was approved by the UMDNJ IRB committee. Collection of BECs from the mouths of animals was approved by the IACUC committees of University of Medicine and Dentistry of New Jersey, Rutgers University, and the IACUC committee of the New England Regional Primate Research Center. Collection methods have been described previously (5, 7). Briefly, BECs collected from the surface of the oral mucosa and/or the dorsal surface of the tongue were obtained by gentle but firm scraping of the mucosa with the flat end of a sterile wooden tongue blade. The blade with collected cells was suspended in 5 ml of phosphate-buffered saline (PBS) and subjected to vortex agitation to remove any residue of sloughed cells from the blade. Cells were then subjected to centrifugation at 100 x g for 3 min, washed, and resuspended in PBS, and cell counting was performed using a hemocytometer to obtain approximately 5 x 104 cells/ml. Cell membrane integrity was assayed by trypan blue exclusion. The presence of endogenous A. actinomycetemcomitans was checked both by culture and by PCR (5, 7). Only BECs that were intact and negative for the presence of A. actinomycetemcomitans were used in in vitro cell binding assays.
Oral epithelial cell binding assay. The binding assay has been described previously (5, 7). Briefly, 200 µl of bacteria, either A. actinomycetemcomitans or E. coli, at a concentration of 5 x 108/ml was added to 200 µl of BECs contained in a 1.5-ml microcentrifuge tube to attain a ratio of 10,000 to 1 (A. actinomycetemcomitans to BEC). To determine A. actinomycetemcomitans binding, the tube containing the mixture of A. actinomycetemcomitans and BECs was rotated at 20 rpm at 37°C for 90 min. For E. coli binding, the tube was rotated at 20 rpm at 4°C overnight. Two hundred microliters of the mixture of bacteria and BECs was placed on top of 10 ml of 5% Ficoll 400 in PBS contained in a 15-ml centrifuge tube. The tube was centrifuged at 100 x g for 5 min to separate the unbound bacteria from the heavier BECs, which pelleted to the bottom of the tube. The supernatant was removed carefully by pipetting. The pellet was resuspended in an equal volume of PBS. Serial dilutions of the resuspension was plated on Trypticase soy agar plates for A. actinomycetemcomitans and on LB plates for E. coli to calculate numbers of bacterial cell CFU/BEC. Background controls included bacteria without BECs and BECs without bacteria added. Binding assays were performed in duplicate on at least three separate occasions. Intactness and viability of BECs were evaluated by light microscopy. More than 95% of the cells were intact and nonviable as determined by trypan blue exclusion.
Preparation of ApiA antiserum. A chemically synthesized peptide with 15 amino acid residues (INENKKDIAINKANC) was selected as the ApiA antigen in order to generate antiserum from rabbits and was based on sequence analysis with blastp (NCBI) and PCGENE (Sigma-Genosys). The N-terminal 14 amino acid residues are located between the 55th and the 69th amino acid residues of the ApiA protein sequence (accession no. AB064943; NCBI). An extra cysteine was linked to the C-terminal end of the 14-mer peptide to facilitate the conjugation of keyhole limpet hemocyanin as the carrier protein. The keyhole limpet hemocyanin-conjugated peptide was used to inoculate New Zealand White rabbits, and the resulting serum was tested for immunoreactivity and specificity using the Western blotting and enzyme-linked immunosorbent assay methods.
Western blot analysis.
E. coli strain DH5
containing pJK654 (apiA+) or pJAK16 vector alone or pJAK16 apiA mutant was stimulated by addition of 1 mM IPTG for 3 h. In addition, JK1051 harboring pJK654 (apiA+) or pJAK16 vector alone or pJAK16 apiA mutant was treated with 1 mM IPTG for 3 h. Three ml of the bacteria containing approximately 3 x 109 cells were centrifuged at 1,500 x g for 5 min. The pellet was resuspended in 50 ml of distilled water, and 10 ml of 6x bacterial lysis buffer was added to the cell suspension to attain a 1x concentration of bacterial lysis buffer (50 mM Tris-Cl, pH 6.8, 100 mM dithiothreitol, 2% sodium dodecyl sulfate, 0.1% bromphenol blue, and 10% glycerol). After boiling for 5 min, the cell suspension was centrifuged at 15,000 x g for 5 min. The supernatant was loaded on a 10% sodium dodecyl sulfate-polyacrylamide gel for electrophoresis. Proteins in the gel were transferred to a 0. 2 mm nitrocellulose membrane (Millipore), and 5% bovine serum albumin was used to block nonspecific binding. ApiA was interrogated with 1:1,000-diluted ApiA antiserum. Alkaline phosphatase-conjugated goat anti-rabbit immunoglobulin G (IgG) was used as the secondary antibody, and the reaction was developed by using the BCIP/NBT system (Bio-Rad).
Assay for blocking ApiA binding by ApiA antiserum. Bacteria were prepared for the binding assay as follows. After two washes with PBS, bacterial strains were suspended in PBS and anti-ApiA antiserum was added to the bacterial suspension in a single dose of 1:25 (vol/vol). A dose-dependent anti-ApiA antiserum evaluation was performed using a series of doses ranging from 1:10 to 1:50 and 1:200. The mixture of bacteria and antiserum was rotated at 20 rpm for 1 h at 37°C, followed by centrifugation at 1,500 x g for 5 min. The supernatant containing unbound antibodies was removed, and the pellet was resuspended in PBS in preparation for the binding assay. Controls consisting of addition of preimmune serum at either 1:10 or 1:25 were prepared. The binding assay was performed as described previously, in this instance pretreating the bacteria to be tested with the preimmune sera and/or the active anti-ApiA antiserum.
Assay of autoaggregation. The autoaggregation assay was modified from the procedures previously reported (3, 12, 13). Briefly, E. coli containing the apiA expression plasmids (pJK654), the aae expression plasmids (pVK43), or the empty vector alone (pJAK16) was cultured in preparation for the E. coli cell clumping and sedimentation assays. The cell clumping assay was performed as follows. After stimulation with IPTG, a 2.5-ml cell suspension was transferred to a 10-ml polypropylene tube. Cells were stained with ethidium bromide and excited with UV light to visually observe cell clumping. In the sedimentation assay, cells were suspended in a quartz cuvette (Perkin-Elmer) and monitored at a spectrum of 590 nm, and time-dependent sedimentation was recorded by noting the optical intensity with a UV-VIS spectrophotometer (UV mini 1240; Shimadzu).
A. actinomycetemcomitans colony phenotype and biofilm formation. A. actinomycetemcomitans growth and colony morphology were examined as described previously (12, 13). Briefly, A. actinomycetemcomitans was grown on solid AAGM agar, and morphology was observed by means of transmitted light microscope. Colony morphology was recorded as rough textured or smooth textured. Biofilm formation was evaluated using a biofilm detachment assay (12, 13). Briefly, A. actinomycetemcomitans strains were adjusted to about 108 ml–1, inoculated into 96-well microtiter plates, and incubated at 37°C in 10% CO2 for 48 h. The plates were washed with PBS twice and stained with 200 µl crystal violet (Fisher) for 2 min. Plates were rinsed with tap water, and 200 µl of ethyl alcohol was added to each well, after which plates were scanned using a microplate reader (Bio-Rad) at 590 nm. Optical intensities were recorded and represented the biofilm formation that was found attached to the wells of the microtiter plate.
Statistical analysis. Multiple group comparisons were assayed with one-way analysis of variance, followed by posthoc testing with the Student-Newman-Keuls test or the Bonferroni correction for selected pairwise comparisons. Significant differences were recorded only if they achieved a level of P values of <0.05.
|
|
|---|
![]() View larger version (20K): [in a new window] |
FIG. 1. A. actinomycetemcomitans binding to mammalian BECs as mediated by ApiA. (A) Western blot identification of ApiA expression in various strains. From left to right: wild-type A. actinomycetemcomitans IDH781N versus JK1051; JK1051 with pJAK16 (empty vector) versus pJK654 (complemented JK1051 with pJAK16 [apiA+]). Anti-ApiA antisera was used to detect ApiA expression. (B) Binding of wild-type IDH781N and the apiA mutant strain to BECs from various mammalian species. Mean number of bacterial cells per BEC was obtained from at least three assays; error bars indicate standard deviations. Solid bars show wild-type strain IDH781N; open bars show apiA mutant strain (the asterisk indicates a P value of <0.05). (C) Effect of anti-ApiA antisera and genetic complementation of apiA on binding to BECs. Antisera reduces binding in wild-type IDH781 (top two bars). Binding of apiA mutant JK1051 harboring plasmid pJAK16 (vector) or pJK654 (vector plus apiA) to human BECs showing no effect (middle bars). pJK654 complemented JK1051 and antisera to ApiA reduced binding (bottom two bars). Complemented strain showed a reduction in binding similar to that of the wild-type strain when treated with anti-ApiA antiserum (compare IDH781N and JK1051 to JK1051 and pJK654). #, P < 0.05, JK1051 harboring pJK654 versus JK1051 harboring pJAK16; *, P < 0.05, ApiA antiserum versus preimmune serum control. (D) Dose-dependent effects of anti-ApiA antisera on IDH781N binding to human BECs. Presented as a percentage of binding compared to results for IDH781N treated with the preimmune sera.
|
In experiments in which the A. actinomycetemcomitans apiA mutant strain JK1051 was complemented, we found that BEC binding was reduced compared to that for wild-type IDH781, suggesting that only partial complementation occurred (Fig. 1C). This reduced binding could be due to either amino acid sequence differences between IDH781 and HK1651 (the sequenced strain of A. actinomycetemcomitans used for our PCR primers) or chloramphenicol selection required to maintain the complementing plasmid. The HK1651 substitution has been done routinely in our laboratory in previous complementation studies with no incident (7, 14). On the other hand, choloramphenicol selection did in fact reduce BEC binding in the complemented strain, JK1051, containing pMB7, an empty plasmid with a chloramphenicol resistance gene, but had no effect on cell growth rate (data not shown).
An apiA aae double-mutant strain (named GJD1) was constructed and tested for binding to BECs and was found to completely abrogate binding to human and Old World primate BECs (Fig. 2A). In comparison to binding of GJD1 to human and Old World primate BECs, binding of GJD1 to rat BECs was slightly but not significantly reduced, while binding to BECs obtained from the mouths of cows was significantly reduced but not abrogated (Fig. 2B) (P < 0.05). As for the single mutations, the binding of JK1051 (apiA mutant strain) to human and Old World primate BECs, although significantly reduced, was still detectable. This was also true when the binding of JK1046 (aae mutant strain) was examined (Fig. 2A).
![]() View larger version (9K): [in a new window] |
FIG. 2. Binding of IDH781, apiA, aae, or apiA aae double mutant strain GJD1 to BECs. (A) Binding of wild-type strain IDH781N; apiA mutant JK1051; aae mutant JK1046; or apiA aae double mutant GJD1 to human BECs. Bars represent the mean; error bars represent the standard deviation. The asterisk indicates a P value of <0.05, versus IDH781; #, P < 0.05, versus GJD1. (B) Binding of wild-type strain IDH781N or the apiA aae double mutant GJD1 to BECs obtained from four mammalian species. *, P < 0.05, IDH781N versus GJD1.
|
![]() View larger version (63K): [in a new window] |
FIG. 3. Phenotypic characterization of wild-type and mutant strains. (A) Colonial morphology of various strains of A. actinomycetemcomitans. Strains JK1051 (apiA), JK1046 (aae), GJD1 (apiA aae), IDH781N (wild type), CU1000 (wild type), and JK1047 (flp-1). (B) Biofilm formation of wild-type and mutant strains. Data are presented as normalized optical densities (OD) using IDH781N as the standard. Binding values are presented as a percentage of the IDH781N OD, which represents biofilm binding to polystyrene. Results for all strains are compared to the OD of wild-type strain IDH781N. Only the JK1047 (flp mutant) showed reduced biofilm binding.
|
(Invitrogen) (Fig. 4). Western blot analysis of E. coli transformed with plasmid pJK654 displayed a specific band detected by anti-ApiA antisera which showed a molecular mass of 100 kDa (Fig. 4A). Further, DH5
/pJK654 cells pretreated with anti-ApiA antiserum exhibited significantly decreased binding to human BECs compared to cells pretreated with preimmune serum (Fig. 4C) (P < 0.05). Moreover, DH5
/pJK654 cells exhibited significantly increased binding to human BECs compared to the binding exhibited by DH5
/pJAK16 (empty plasmid) (Fig. 4B) (P < 0.05). In comparison, DH5
/pJK654 cells did not bind to human tongue epithelial cells.
![]() View larger version (24K): [in a new window] |
FIG. 4. Expression of ApiA in E. coli. (A) Western blot analysis of extracts from E. coli harboring pJAK16 (vector alone) or pJK654 (vector + apiA). Blots were probed with rabbit antiserum raised to ApiA. (B) Binding of E. coli cells harboring pJAK16 or pJK654 to human BECs and human tongue epithelial cells (TECs). E. coli cells were grown in medium containing 0 or 1 mM IPTG. The asterisk indicates a P value of <0.05, pJK654 (vector + apiA) versus pJAK16 (vector alone). (C) Binding of E. coli cells harboring pJK654 to human BECs. Bacterial cells were pretreated with preimmune serum or anti-ApiA antiserum prior to the binding assay. The asterisk indicates a P value of <0.05, versus the anti-ApiA antiserum pretreatment group.
|
/pJK654 to BECs isolated from three Old World primates, three New World primates, and three nonprimate mammals (Fig. 5). Significantly more DH5
/pJK654 cells bound to BECs from Old World primates than to BECs from New World primates, although in one of three experiments, minimal binding was found in the common marmoset. DH5
/pJK654 cells did not bind at detectable levels to rat, cow, or horse BECs.
![]() View larger version (7K): [in a new window] |
FIG. 5. Binding of E. coli cells harboring ApiA expression plasmid pJK654 to BECs isolated from mammalian species. Bars represent means of triplicate assays, and error bars show standard deviations. E. coli bound only to Old World primate BECs; however, in one of three assays the common marmoset showed minimal binding.
|
In an effort to better understand the ApiA adhesin phenotype in terms of its autoaggregating ability, we chose to examine ApiA expression in E. coli where other confounding attachment characteristics, as seen in wild-type A. actinomycetemcomitans, could be eliminated (Fig. 6). Experiments demonstrated that 1 h after a vigorous vortex agitation, DH5
/pJK654 cells formed autoaggregative clumps and left a relatively clear supernatant above the sedimented cells. Cell suspensions of DH5
/pJAK16 and DH5
/pVK43 (expressing Aae) appeared turbid and homogeneous in comparison to ApiA-expressing E. coli (Fig. 6A). When the cells were suspended in a quartz cuvette and monitored by light at 590 nm, time-dependent sedimentation was recorded for ApiA (Fig. 6B). Unlike the case with wild-type A. actinomycetemcomitans, autoaggregation by E. coli was easily dispersed by vortex agitation.
![]() View larger version (37K): [in a new window] |
FIG. 6. Autoaggregation of E. coli expressing ApiA and Aae. (A) E. coli strain harboring pJAK16 (vector), pJK654 (apiA+), or pVK43 (aae+) is seen in a visual autoaggregation assay. Cells were stained with ethidium bromide and excited by a UV light source. The cells harboring the apiA gene formed clumps that settled to the bottom of the tube, while the other strains remained in a homogeneous suspension. (B) Plot of the optical density of cell suspensions of E. coli expressing ApiA and Aae and an E. coli vector control. A 1-ml cell suspension was added to a quartz cuvette and monitored by light at 590 nm. The optical density (OD) was recorded at 2-min intervals. Data are presented as a percentage of the OD seen at zero time, where the cell suspension was homogeneous. Only the cells expressing ApiA (pJK654) sedimented.
|
|
|
|---|
With that in mind, our findings indicate that ApiA and Aae are two prominent adhesins that mediate in vitro attachment of A. actinomycetemcomitans to BECs derived from humans and Old World primates. Evidence indicates that the primary reservoir for this organism is the oral cavity of humans (19), although A. actinomycetemcomitans has been isolated as an infectious contaminant from sites distant from the oral cavity in subacute bacterial endocarditis, pneumonia, brain abscesses, and kidney failure (30). In addition to humans and Old World primates, A. actinomycetemcomitans has also been isolated from the oral cavity of cows and rats, which taken together comprise the known natural host range for A. actinomycetemcomitans (4, 7). The results derived from this study suggest that both ApiA and Aae are required for efficient binding of A. actinomycetemcomitans to human BECs and confirm the findings of others that indicate that both Aae and ApiA function as outer membrane protein adhesins (1, 7, 17).
In contrast to data derived from human and monkey BECs, neither ApiA nor Aae appear to be the main adhesins responsible for the specific binding of A. actinomycetemcomitans to BECs derived from rats. Previously we demonstrated that an aae mutant had little if any effect on binding of A. actinomycetemcomitans to rat or cow BECs (7). In experiments reported in this article, the apiA mutant and the apiA aae double mutant reduced binding to rat BECs, but only minimally. Moreover, the apiA aae double mutant caused a significant decrease but did not abrogate binding to cow BECs. However, as mentioned, the double mutant did eliminate binding to BECs derived from humans and Old World primates. These results suggest that although the ApiA adhesin may have some effect on binding to cow BECs, other as yet unidentified adhesins may be present in cows as well as rats.
Furthermore, with respect to E. coli expression of ApiA and Aae, binding studies showed that a higher concentration of E. coli expressing ApiA is required to exhibit initial detectable binding compared to results for E. coli expressing Aae. This result could be due to differences in E. coli protein expression, or alternatively Aae expression may exhibit higher affinity for BECs. The latter hypothesis is supported by data that demonstrate that an A. actinomycetemcomitans Aae mutant requires a higher concentration of cells per BEC than its wild-type strain to achieve detectable levels of attachment, suggesting that Aae has a higher affinity for BECs, although more work needs to be done in this area (7). In contrast, at higher concentrations of bacterial cells added to BECs, the total numbers of CFU/BEC required were higher for E. coli expressing ApiA than for E. coli expressing Aae. These results suggest that autoaggregation was involved in E. coli expressing ApiA binding to BECs (17). The autoaggregative property of ApiA expressed in E. coli was further demonstrated by examining its ability to sediment as early as 20 min after vigorous vortex agitation (Fig. 6), a property that was not displayed in E. coli expressing Aae.
In conclusion, based on the data reported, we now can say convincingly that ApiA plays an important role in modulating A. actinomycetemcomitans binding to human and Old World primate BECs (7). Moreover, we are the first to report that a double knockout of aae and apiA completely abrogates the binding of A. actinomycetemcomitans to BECs from human and Old World primate BECs. If in fact, BECs provide A. actinomycetemcomitans with a protected domain in the oral cavity (23), then the data identifying the importance of the action of these two adhesins could have significant clinical and therapeutic implications.
Although ApiA and Aae are both autotransporter proteins, the surface-exposed domains of ApiA and Aae are not homologous. It is interesting to note that A. actinomycetemcomitans cells produce leukotoxin, a member of the RTX family of secreted toxins (9). As in the case of both ApiA and Aae, Leukotoxin interacts with PMNs and macrophages derived from humans and Old World primates but not with those derived from New World primates or other nonprimate mammals (27). It is clear that these surface-expressed proteins each have different host receptors. These findings suggest that the evolution of host specificity and host cell tropism in A. actinomycetemcomitans has occurred through a complicated process of natural selection resulting from multiple cell surface interactions (20, 25).
Our appreciation is extended to the National Institutes of Dental and Craniofacial Research for providing support in the form of grant no. DE-016306 to D.H.F.
Published ahead of print on 9 July 2007. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»